BioSpecifics Technologies Corp.  

(Public, NASDAQ:BSTC)   Watch this stock  
Find more results for Marc Guitman�
39.01
+0.96 (2.52%)
Oct 22 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 37.77 - 39.81
52 week 17.57 - 39.81
Open 38.53
Vol / Avg. 93,610.00/46,238.00
Mkt cap 246.45M
P/E 63.81
Div/yield     -
EPS 0.61
Shares 6.48M
Beta 1.08
Inst. own 47%
Sep 26, 2014
Biospecifics Technologies Corp at BioCentury Publications NewsMakers in the Biotech Industry
Sep 9, 2014
Biospecifics Technologies Corp at Rodman & Renshaw Global Investment Conference
Aug 11, 2014
Q2 2014 Biospecifics Technologies Corp Earnings Call
Aug 11, 2014
Q2 2014 Biospecifics Technologies Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '14) 2013
Net profit margin 21.79% 36.54%
Operating margin 33.01% 54.91%
EBITD margin - 55.36%
Return on average assets 9.28% 25.39%
Return on average equity 9.69% 26.57%
Employees 5 -
CDP Score - -

Address

35 WILBUR ST
LYNBROOK, NY 11563
United States - Map
+1-516-5937000 (Phone)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

BioSpecifics Technologies Corp. (BioSpecifics) is a biopharmaceutical company involved in the development of an injectable collagenase for multiple indications. The Company has a development and license agreement with Auxilium Pharmaceuticals, Inc. (Auxilium) for injectable collagenase (which Auxilium has named XIAFLEX) for clinical indications in Dupuytren�s contracture, Peyronie�s disease and frozen shoulder (adhesive capsulitis), and Auxilium has an option to acquire additional indications that it may pursue, including lipomas and cellulite. Auxilium has an agreement with Pfizer, Inc. (Pfizer), pursuant to which Pfizer has the right to market XIAFLEX for Dupuytren�s contracture and Peyronie�s disease in 27 member countries of the European Union and 19 other European and Eurasian countries, and under the registered trademark XIAPEX (collagenase clostridium histolyticum).

Officers and directors

Thomas L. Wegman President, Principal Executive Officer, Principal Financial Officer, Director
Age: 59
Bio & Compensation  - Reuters
Mark N. Wegman Ph.D. Director
Age: 64
Bio & Compensation  - Reuters
Toby Wegman Director
Age: 79
Bio & Compensation  - Reuters
Paul A. Gitman M.D. Independent Director
Age: 73
Bio & Compensation  - Reuters
George M. Gould J.D. Independent Director
Age: 76
Bio & Compensation  - Reuters
Michael Schamroth Independent Director
Age: 74
Bio & Compensation  - Reuters